Darolutamide for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 11 Dec 2023: Trial started, NCT06177015
  2. 20 Dec 2023: Trial registered, NCT06177015

The trials

NCT05826509: SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

State
Under way
Phase
Phase 2
People
240 planned
Started
10 Aug 2023
Primary completion
Feb 2031
Arms
Experimental arm
Results
None posted
  1. 24 Apr 2023: Trial registered
  2. 10 Aug 2023: Trial started

NCT06177015: Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

State
Under way
Phase
Phase 3
People
200 planned
Started
11 Dec 2023
Primary completion
31 Dec 2025
Arms
Intermittent treatment group
Results
None posted
  1. 11 Dec 2023: Trial started
  2. 20 Dec 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Darolutamide intermittent, Nubeqa, Peri-operative darolutamide + surgery..

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.